Business Development Director – UK & Nordics

New Yesterday

Business Development Director – UK & Nordics

Founded in 1974, by Bernard Jambon and JL Menard, MAPI Group has grown both organically and through acquisition over the past 35 years. Today, MAPI Group employs over 450 people in North America, Europe and Asia.

MAPI is structured into three divisions which comprise a number of separate legal entities:

Late Phase CRO

Strategic Consulting

Linguistic Validation

A separate entity, the MAPI RESEARCH TRUST is a non-profit association concerned with the promotion of PRO evaluations and worldwide distribution of information concerning these measures.

The MAPI Group consists of a number of companies; all dedicated to providing unique solutions to aid and improve drug development to meet patient and market needs.

MAPI group anticipates change and develops services and solutions designed to respond to a full range of evaluation needs. Their experience comes from extensive partnerships with industry, health authorities, investigators and patients.

MAPI Group’s strength lies not only in its breadth of experience and expertise, but in the total dedication to research conducted by dynamic, specialised teams, backed up by powerful technical and logistics support.

Late Phase CRO

REGISTRAT-MAPI

REGISTRAT-MAPI is the industry’s largest clinical research organisation dedicated solely to “real world” clinical research. Successfully drawing upon their strategic and operational expertise to design and conduct global late phase studies and to develop partnerships with biopharmaceutical and medical device company clients.

As the demand for Late Phase development grows significantly both in size and complexity, REGISTRAT-MAPI continues to lead the way through innovation in registries, safety studies and product utilisation studies.

With its head office in Lyon, France and further operations throughout Europe and United-States, REGISTRAT-MAPI specialise, among others, in:

Providing a complete Spectrum of Integrated Late Phase Services:

Evidence-based research is increasingly desired by pharmaceutical companies due to recent FDA and EMEA initiatives as well as changing requirements from health care payers (government and private insurers). The market for phase IV post-approval research is estimated at $12 billion and growing at 23% per year . REGISTRAT-MAPI is currently the market leader in France and a major player in Europe in Late Phase studies (Phase IV and Observational).

Given REGISTRAT-MAPI’s leading position in Europe, unique range of expertise and experience already gained through its numerous key clients, the Group is well positioned to win large scale international studies, negotiate preferred provider agreements and become a leading global player in the Late Phase segment.

Context of the Role

It is widely recognised that the demand for CRO services will continue to grow over the coming years with some predicting that this will be as much as 20% per annum . The market for Phase IV post-approval research is estimated at $12bn and growing by 23% per year . REGISTRAT-MAPI is uniquely positioned to take advantage of this growth for several reasons:

For further information please review the company and group websites at:
www.registratmapi.com
www.mapigroup.com

Job Description

Primary Purpose of the Job

Essential Functions:

Accountabilities:

Personal Style

Person Specification

Package

Location: Details upon on application
Salary: £Commensurate with experience
Reference: PSL4015

Pharma-Search Ltd,
Company Number:
07441348

#J-18808-Ljbffr
Location:
United Kingdom
Job Type:
FullTime
Category:
Management & Operations